BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1222 related articles for article (PubMed ID: 14578539)

  • 1. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs associated with attempted suicide among individuals with bipolar disorder.
    Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
    J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limiting access to psychiatric services can increase total health care costs.
    Horn SD
    J Clin Psychiatry; 2003; 64 Suppl 17():23-8. PubMed ID: 14680424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care resource use associated with integrated psychological treatment.
    Vasiliadis HM; Briand C; Lesage A; Reinharz D; Stip E; Nicole L; Lalonde P
    J Ment Health Policy Econ; 2006 Dec; 9(4):201-7. PubMed ID: 17200597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
    McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
    J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.
    Dickey B; Normand SL; Eisen S; Hermann R; Cleary P; Cortés D; Ware N
    Med Care; 2006 Sep; 44(9):827-34. PubMed ID: 16932134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National trends in psychotropic medication polypharmacy in office-based psychiatry.
    Mojtabai R; Olfson M
    Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explicit versus implicit review to explore combination antipsychotic prescribing.
    Wheeler A
    J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic medication utilization trends among Texas veterans: 1997-2002.
    Yang M; Barner JC; Lawson KA; Rascati KL; Wilson JP; Crismon ML; Worchel J; Mascarenas CA
    Ann Pharmacother; 2008 Sep; 42(9):1229-38. PubMed ID: 18682544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.